Recruiting NCT07214675

The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy

No phase Interventional Benign Prostatic Hyperplasia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: HistoSonics Edison System.
Who it may be relevant to: Registry conditions: Benign Prostatic Hyperplasia. Basic parameters: from 50 years · Male.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Hong Kong
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The purpose of this trial is to evaluate the safety of histotripsy using the HistoSonics Edison System for treatment of BPH.

Detailed description

This is a prospective multi-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Histotripsy System for treatment of BPH. Following histotripsy, subjects will undergo imaging ≤ 72 hours post-index procedure. Additionally, subjects will be followed at 30-day, 90-day and 180-day timepoints.

Interventions

Device HistoSonics Edison System
The HistoSonics Edison System is intended for the non-invasive mechanical destruction of prostate tissue for the treatment of BPH using histotripsy, a non-thermal, mechanical process of focused ultrasound.

Primary outcome measures

Number of Index-Procedure Related Adverse Events Classified by Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE) [Time frame: 30 days post histotripsy procedure]

Eligibility criteria

Inclusion criteria

Subject is ≥ 50 years of age.
Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
Subject is diagnosed with BPH.
Subject has a Body Mass Index (BMI) < 27.
Subject has an I-PSS ≥ 15.
Subject has a prostate volume > 30 mL and ≤ 150 mL.
Subject has a Qmax ≤ 15 mL/s with a voided volume of ≥ 125 mL during a uroflow test.
Subject accepts the potential loss of ejaculatory function.
Subject can tolerate general anesthesia. Index-Procedure Imaging Inclusion (Assessed day of procedure)
Subject has an adequate acoustic window to visualize the prostate using the HistoSonics Edison System.
Target treatment volume is ≥ 1 cm from the rectum as visualized on ultrasound, CT or MR imaging.

Exclusion criteria

Subject has a life expectancy of less than one (1) year.
Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
Subject has a post-void residual ≥ 150 mL confirmed via ultrasound.
Subject has an estimated glomerular filtration rate (eGFR) ≤ 50 mL/min, ≤ 14 days prior to the planned index procedure date.
Subject has uncorrectable coagulopathy.
Subject has an International Normalized Ratio (INR) value ˃ 2.0, ≤14 days prior to the planned index procedure date.
Subject has had a prostatectomy.
Subject has acute prostatitis.
Subject has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome.
Subject has had a urinary tract infection (UTI) ≤ 3 months prior to the planned index procedure date.
Subject has bladder stones.
Subject is catheter dependent or has a history of intermittent self-catheterization.
Presence of prostatic calcifications in the planned treatment volume (PTV).
Presence of permanent radioactive implants in the rectal wall.
Subject has has a major abdominal or rectal surgery that inhibits visualization of the prostate.
Subject has undergone prior locoregional therapy (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
Subject has planned locoregional therapy 6 months post index procedure (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
In the investigator's opinion, histotripsy is not a treatment option for the subject.
Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
Subject's prostate is not treatable by the System's working ranges (refer to User Guide).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: N/A
Model: Single group
Masking: Open label
Primary purpose: Treatment

Study locations

Hong Kong · 1 center

Prince of Wales Hospital — Shatin

Identifiers

NCT: NCT07214675 · CSP5895

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗